Long-term, Open Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of QCC374 in Patients With Pulmonary Arterial Hypertension (PAH)

Trial Profile

Long-term, Open Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of QCC374 in Patients With Pulmonary Arterial Hypertension (PAH)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs QCC 374 (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 29 Mar 2017 Planned End Date changed from 1 Apr 2019 to 2 Oct 2019.
    • 29 Mar 2017 Planned primary completion date changed from 1 Apr 2019 to 2 Oct 2019.
    • 29 Mar 2017 Planned initiation date changed from 1 Jul 2017 to 2 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top